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Peptoids successfully inhibit the 
growth of gram negative E. coli 
causing substantial membrane 
damage
Biljana Mojsoska1, Gustavo Carretero1,2, Sylvester Larsen1,3, Ramona Valentina Mateiu4 & 
Håvard Jenssen1
Peptoids are an alternative approach to antimicrobial peptides that offer higher stability towards 
enzymatic degradation. It is essential when developing new types of peptoids, that mimic the 
function of antimicrobial peptides, to understand their mechanism of action. Few studies on the 
specific mechanism of action of antimicrobial peptoids have been described in the literature, despite 
the plethora of studies on the mode of action of antimicrobial peptides. Here, we investigate 
the mechanism of action of two short cationic peptoids, rich in lysine and tryptophan side chain 
functionalities. We demonstrate that both peptoids are able to cause loss of viability in E. coli 
susceptible cells at their MIC (16–32 μg/ml) concentrations. Dye leakage assays demonstrate slow and 
low membrane permeabilization for peptoid 1, that is still higher for lipid compositions mimicking 
bacterial membranes than lipid compositions containing Cholesterol. At concentrations of 4 × MIC 
(64–128 μg/ml), pore formation, leakage of cytoplasmic content and filamentation were the most 
commonly observed morphological changes seen by SEM in E. coli treated with both peptoids. Flow 
cytometry data supports the increase of cell size as observed in the quantification analysis from the SEM 
images and suggests overall decrease of DNA per cell mass over time.
Traditional antibiotics gradually lose their efficacy against many pathogens due to fast resistance development by 
the microorganisms1. Moreover, the number of new antibiotics developed and approved is steadily decreasing2. 
Therefore there is an urgent demand for development of novel antimicrobial drugs that offer different treatment 
strategies. Antimicrobial peptides (AMPs), are a class of antimicrobial agents that have long served all living 
organisms in combating infectious diseases by their ability to kill or inhibit the growth of pathogens3,4. There is 
increasing evidence indicating that the primary direct antimicrobial activity of cationic antimicrobial peptides is 
through interaction with anionic bacterial surfaces4,5. On the other hand, the non-membrane disruptive mecha-
nisms are often ascribed to the ability of certain AMPs to bind to intracellular targets and act on DNA, RNA and 
protein synthesis3–5. Other AMPs use a combination of membrane and intracellular activity, thus hampering their 
development as novel drug candidates with a specific target. Despite their effectiveness, one of the limitations of 
AMPs is their low bioavailability as a result of enzymatic degradation6. Therefore, AMPs have been subjected to 
various modifications to design novel classes of potent antimicrobials with improved stability and activity profiles, 
namely peptidomimetics. Peptoids, are oligomers of N-substituted glycines, a class of compounds that mimic the 
structure of peptides7. For more than 15 years, the research in peptoid synthesis and application, has dramatically 
increased due to their potential as compounds with broad biological activity profiles. Recently, studies have also 
demonstrated their antimicrobial properties8–10. Peptoids are less prone to enzymatic and proteolytic degradation 
and are more membrane permeable than peptides6,11. We and others, have previously demonstrated that the anti-
microbial activities are retained upon translation of peptides into peptoids, thus suggesting that this class of anti-
microbials acts via similar mechanisms8,12. Short cationic peptoids are shown to be able to decrease the number 
1Department of Science and Environment, Roskilde University, Universitetsvej 1, Postboks 260,4000 Roskilde, 
Denmark. 2Department of Biochemistry, Institute of Chemistry. University of São Paulo, São Paulo, Brazil. 
3Department of Clinical Immunology, Naestved Hospital, Naestved, Denmark. 4DTU CEN, Center for Electron 
Nanoscopy, Technical University of Denmark, Kgs Lyngby, Denmark. Correspondence and requests for materials 
should be addressed to H.J. (email: jenssen@ruc.dk)
received: 06 July 2016
accepted: 10 January 2017
Published: 14 February 2017
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 7:42332 | DOI: 10.1038/srep42332
of viable bacterial cells, form pores, and bind to intracellular targets such as DNA13,14. Other have reported that 
the mechanism behind their bacterial killing is primarily associated with membrane disruption usually by pore 
forming mechanisms13,15. In an attempt to better understand the mechanism by which the most selective short 
cationic Peptoids 1 and 2, impair the ability of Gram-negative E. coli to divide, this paper describes their killing 
kinetics, membrane activity and their effect on E. coli morphology. Data clearly demonstrate that at peptoid MIC 
concentrations (Peptoid 1 MIC = 16 μ g/ml, Peptoid 2 MIC = 32 μ g/ml), the bacterial growth is successfully inhib-
ited without any degree of membrane disruption, and a small degree of disruption is only detected at 4 × MIC.
Results and Discussion
In Vitro Antibacterial Activity. We have previously reported the broad spectrum activity of a library of cat-
ionic tryptophan rich peptoids against six bacterial strains and compared those activities with the ones of similar 
antimicrobial peptides12,16. In addition, the hemolytic activity and cytotoxicity against HeLa cells were analysed, 
altogether demonstrating good selectivity profiles for these peptoids. Two peptoids showed good selectivity index 
values with respect to their activity against E. coli and their haemolytic values and were therefore chosen for further 
studies (Table 1). Both peptoids have relatively short sequences (9 residues, Fig. 1) and exhibit MIC ( ≤ 22.2 μ M) 
values that are comparable to that of the antimicrobial peptide indolicidin (Table 1) and are within the range of 
other antimicrobial peptoids reported in the literature8,17.
E. coli killing kinetics. In order to differentiate between bacteriostatic and bactericidal mode of action of 
peptoids 1 and 2, E. coli cultures were challenged with different concentrations in a period of 6 hours and growth 
Compound/Strain
Minimal Inhibitory Concentration [MIC μg/ml 
(μM)]a
Hemolytic Concentration 
[μg/ml (μM)]b
Selectivity 
Indexc Cytotoxicity [μg/ml]d
E. coli P. aeruginosa
HC10 HC10/MIC IC50ATCC 25922 63103 ESBLe PAO1 H1027 MDRf
Peptoid 1 16 (10.8) 16 (10.8) 16 (10.8) 2 (1.35) 128 (87) 8–68 104
Peptoid 2 32 (22.2) 8 (5.5) 32 (22.2) 4 (2.7) 128 (89) 4–32 110
Indolicidin 32 (16.8) ND 32 (16.8) ND 64 2–4 ND
Table 1.  Biological activities of Peptoids 1 and 2. Median MIC values representative for 3–5 replicates are 
given in μ g/ml. aDue to different molecular weights; MIC values are also given in μ M, seen in brackets. ND 
signifies not determined. bThe hemolysis results are from 3 individual experiments using different blood donors. 
cThe selectivity index is the quotient of 10% hemolysis and the lowest and highest MIC of the bacterial strains. 
dCytotoxicity is reported as IC50, designated as concentration found to inhibit the metabolic activity of HeLa 
WT cells using the colorimetric tetrazolium salt based MTS assay. eExtended spectrum beta-lactamase. fmulti-
drug resistant P. aeruginosa.
Figure 1. Chemical structures of peptoids. (A) Peptoid 1 and (B) Peptoid 2.
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inhibition patterns were compared. Data supports the inhibition capacity of both peptoids which show clear 
concentration dependent inhibition of E. coli. Both Peptoids 1 and 2 at 1 × MIC concentrations exhibit bacte-
riostatic mode of action on E. coli growth (Fig. 2A,B). The slow killing for Peptoids 1 and 2 may indicate that at 
MIC concentration these peptoids target intracellular metabolic processes that cause bacterial growth inhibition. 
With respect to this observation, delayed killing kinetics have been observed for AMPs that target intracellular 
compartments18,19. These could be inhibition of DNA synthesis or cell filamentation as observed for bacteriostatic 
antimicrobial compounds20. At 2 × MIC concentrations different killing kinetics are observed, where Peptoid 2 
acts via bactericidal mechanism (Fig. 2A). The observed difference may be partly due to the different hydropho-
bicity profiles of these peptoids measured by retention times on HPLC. Here, Peptoid 2 is globally more hydro-
phobic and this property could enhance its insertion into bacterial membranes. Similar killing kinetic profiles 
as Peptoid 2 have been previously observed for other antimicrobial peptidomimetics13,21–23. At 4 × MIC concen-
trations, both peptoids show significant bactericidal behaviour which is marginally higher than that shown for 
ciprofloxacin, an antibiotic that prevents DNA replication, recombination and repair (Fig. 2B)24. The fast killing 
kinetics is still not higher than that reported in the literature for polymyxin B, a fast permeabilizing antimicrobial 
peptide, where upon reaching a threshold concentration, the accumulated peptide molecules of polymyxin B can 
rapidly cause bacterial death25.
Quantification of membrane permeabilization. The mechanism of action of antimicrobial peptides 
and related mimetics that carry net positive charge and moderate hydrophobicity on bacteria is generally asso-
ciated with fast killing kinetics as a result of membrane permeabilization18,23,26–28. To investigate whether the 
bactericidal effect observed from the killing kinetics experiments is related to the ability of the peptoids to disrupt 
bacterial membranes, we calculated the percentile of viable and non-viable cells using Live/Dead quantification 
assay. In this assay two nucleic acid dyes, syto 9 green and propidium iodide (PI) red, that have different mem-
brane permeabilities were used as indicators of live bacteria with intact membranes versus dead bacteria with 
compromised membranes, respectively. Peptoid 1 caused gradual decrease of the number of PI stained cells at 
1 × MIC concentration. In response to Peptoid 2 treatment, 90 percent of E. coli showed high membrane perme-
abilization within one hour of treatment, that supports the observation for the higher potency exhibited by this 
peptoid from the killing kinetics experiments (Fig. 3). Importantly, the activity of both peptoids remains stable 
after 5 hours of incubation. This is in contrast to the activity observed for the peptide from which these peptoids 
are derived, where re-established growth is observed within 2 hours of peptide administration16.
Release of fluorescent dyes from different liposome compositions. Two fluorescent dye leak-
age assays were used to assess the disruptive ability of peptoids. The two assays use similar fluorescent dyes, 
carboxyfluorescein (CF) and calcein to measure the leakage from the liposomes. These two assays offer infor-
mation on the electrostatic interaction with membranes mimicking bacterial surfaces and interaction with 
Figure 2. Killing kinetics. (A) Optical density measurements at 600 nm of exponentially growing E. coli, with 
and without Peptoid 1 at 1 × MIC (16 μ g/ml), 2 × MIC (32 μ g/ml) and 4 × MIC (64 μ g/ml) and Peptoid 2 at 
1 × MIC (32 μ g/ml), 2 × MIC (64 μ g/ml) and 4 × MIC (128 μ g/ml) concentrations. (B) Time-kill study of E. coli 
ATCC 25922 challenged with 1 × MIC (16 μ g/ml, 32 μ g/ml and 0.05 μ g/ml) and 4 × MIC (64 μ g/ml, 128 μ g/ml 
and 0.2 μ g/ml) concentrations of Peptoids 1 and 2 and ciprofloxacin, respectively. For both experiments E. coli 
cultures are in log phase at 2–4 × 107 CFU/ml. Data represents mean and SEM of 3 independent experiments.
www.nature.com/scientificreports/
4Scientific RepoRts | 7:42332 | DOI: 10.1038/srep42332
membranes with different fluidities. Bacterial membranes have a highly negative transmembrane potential 
(approximately − 120 mV) in contrast to the weak membrane potential maintained by mammalian cells29. 
Thus they attract positively charged compounds such as cationic peptoids. Therefore, to test the existence of 
a specific interaction between Peptoid 1 and the glycerol polar headgroup of palmitoyl-2-oleoyl-sn-glycero− 
3-phospho-(1′ -rac-glycerol) (POPG) or, if the interactions are purely electrostatic, carboxyfluorescein (CF) leak-
age assays from liposomes of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) containing 20 mol % of 
1-hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phosphate (POPA) or POPG were performed initially. Both 
POPA and POPG are negatively charged phospholipids but with different polar headgroup structures; while PA 
phospholipid only has a phosphate group linked to C3 of the glycerol moiety, PG has a phosphoglycerol group at 
this same position. Liposomes containing 20 mol % of negatively charged POPA showed to be more susceptible to 
Peptoid 1 when compared to liposomes with 20 mol % of POPG (Fig. 4). This indicates that there is no specificity 
in peptoid binding to PG. Again, the greater extent of dye release from liposomes with 40 mol % of POPG com-
pared to 20 mol % of POPG shows the importance of electrostatic interactions between the peptoid and liposomes 
and that its activity increases with the increase of overall net surface charge (Fig. 4).
Furthermore, besides electrostatic interactions, hydrophobic side chain functionalities contribute greatly to 
the peptoid–membrane interactions. Tryptophan-like residues have strong membrane disruptive activities due to 
their ability to interact with the membrane interface. This activity is assigned partly due to the flat and rigid struc-
ture of the indole ring that may favour alignment of the side-chain in the membrane interface region4. To evaluate 
the permeability of the peptoids to membranes, we used the calcein leakage assay where calcein was encapsulated 
in two different combinations of selected lipids POPC:POPG (7:3) and POPC, POPG and Cholesterol (5:2:3). 
The membranes of mammalian cells have sterol molecules such as Cholesterol in their membrane compositions 
and this property can prevent peptoid insertion in the lipid bilayers. We used membrane composition containing 
POPC, POPG and Cholesterol (5:2:3), as reported previously, to mimic membrane environment with decreased 
fluidity while retaining negative charge to ensure peptoid binding16,30. In addition, the liposomes composed of 
POPC, POPG and Cholesterol also mimic membrane compositions of some of the membranes of tumour cells 
Figure 3. Quantification of viable bacteria using Live/Dead staining. Percentile live bacteria treated with 
Peptoid 1 at 1 × MIC (16 μ g/ml), 2 × MIC (32 μ g/ml) and 4 × MIC (64 μ g/ml) and Peptoid 2 at 1 × MIC (32 μ 
g/ml), 2 × MIC (64 μ g/ml) and 4 × MIC (128 μ g/ml) (Eq. 1 see Experimental Section). 100% is set as the value 
from untreated samples at time zero. Results are from 3 independent experiments with SEM error bars.
Figure 4. Carboxyfluorescein release for Peptoid 1. Carboxyfluorescein release over time from three liposome 
compositions at different Peptoid 1 concentrations is shown.
www.nature.com/scientificreports/
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and neurons, even though POPG is not found as a part of the composition of mammalian membranes31. The total 
amount of released calcein was monitored and the degree of membrane permeabilization of the peptoids was 
calculated using Equation 2. Distinct tendency to lyse liposomes mimicking bacterial membranes (POPC:POPG) 
over liposomes mimicking less fluidic membranes, was observed for Peptoid 1, in contrast to the indiscrimina-
tive membrane permeabilization activity of the control peptide melittin that acts via the toroidal pore formation 
mechanism (Fig. 5A,B)32. Membrane permeabilzation is expected for the peptoids in this study because of their 
structural compositions. Short tryptophan rich cationic peptides have been reported to exhibit high membrane 
activity on E. coli where the peptide with the highest tryptophan content (2 W) and charge (+ 9) showed high-
est percentage of membrane permeabilization (approximately 60%)33. Similarly, the peptoids in this study are 
rich in charged (+ 4) and tryptophan-like residues (4 W) which are expected to contribute significantly to the 
observed membrane permeabilizing properties. The permeability of peptoid 1 was greater for liposome com-
positions that mimic bacterial membranes (Fig. 5). Maximum calcein leakage (< 30%) was observed from sub 
MIC concentrations of Peptoid 1 and an increase in the peptoid concentration from 6.25 to 25 μ g/ml did not 
contribute to an increase in the calcein release from these liposomes (Fig. 5B), thus indicating that Peptoid 1 only 
has a weak membrane activity. The membrane activity is also much lower than the one observed for structurally 
similar GN-4 antimicrobial peptide we have published previously16. The unique physiochemical properties of 
peptoids such as loss of hydrogen donation and backbone chirality may be expected to impact the membrane 
interactive properties when compared with peptides. However, not all antimicrobial peptides insert and disrupt 
the membranes or form pores. Studies on mechanism of action of cationic tryptophan rich peptides have shown 
that they either primarily lyse the membrane of Gram-negative bacteria by pore formation or they translocate 
and act on internal targets34. The overall total thickness of the membrane of Gram-negative bacteria varies from 
30–50 nm. In order for a peptide or peptidomimetic to form a pore in the membrane, it has to be long enough to 
span the membrane e.g. barrel-stave model. Some peptides are too short to span the membranes35,36. They usually 
induce pore formation via a toroidal model by stabilizing the lipid pore and forming a peptide-lipid complex37. 
Indolicidin, a short (13 residue), tryptophan rich, extended structure cationic peptide, is able to cause leakage of 
calcein and carboxyfluorescein from negatively charged liposomes via non-membrane pore formation mecha-
nism, but rather via translocation of dye molecules across the membrane in the form of dye-peptide complexes35.
Concentration dependent calcein release was observed from liposomes containing Cholesterol, but with a 
significantly slower release rate and a lower threshold, which is in agreement with the low toxicity reported for 
Figure 5. Calcein release from two liposome compositions, POPC:POPG (7:3) and POPC:POPG:Cholesterol 
(5:2:3) for (A) Melittin and (B) Peptoid 1. Calcein release as a result of different concentrations and 
concentration dependent release over time is shown. Results are from minimum of 3 independent experiments 
with SEM error bars.
www.nature.com/scientificreports/
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Peptoid 1 at concentration as high as 4 × MIC. Calcein leakage in a concentration dependent manner is also 
observed for antimicrobial peptides38. This concentration dependent activity of antimicrobial peptides has been 
explained by a two-state model37. This model illustrates initial binding of peptide monomers parallel to the plane 
of the membrane. The peptides are then dispersed all across the membrane without causing pore formation. As 
the concentration of the peptide increases, thinning and formation of transmembrane pores takes place37. Similar 
membrane thinning has been reported for indolicidin35,39. Our findings suggest that the release of calcein upon 
addition of Peptoid 1 is concentration dependent and significantly lower than the total calcein release observed 
for melittin (Fig. 5A,B)40. The total dye leakage together with the results on the bacterial viability quantification 
at concentrations around 1× and 2 × MIC of Peptoid 1, are in agreement with the killing kinetics experiments 
indicating that the growth inhibition is partially exerted by some degree of membrane damage that does not 
include toroidal pore formation.
Changes in Membrane Morphology of bacteria upon peptoid treatment. E. coli were inspected 
using scanning electron microscopy to visualize any morphological changes (membrane disruption, cell elonga-
tion, etc.) after peptoid treatment. Untreated bacterial cells appear with smooth surfaces whereas considerable 
roughening and leakage of cytoplasmic content is observed for peptoid treated bacteria (Figs 6 and 7). The SEM 
micrographs show membrane damage upon treatment with both peptoids at 1× and 4 × MIC, with a more pro-
nounced effect at 4 hours (Figs 6 and 7). These cellular changes are related to the growth inhibitory activities 
observed at 1× and 4 × MIC concentrations. Membrane disintegration is expected for these peptoids due to 
the presence of four tryptophan like side chains which are strongly associated with high affinity for the interfa-
cial region of bilayers41. Similar changes in bacterial surfaces, such as membrane damage and blebs have been 
observed both for antimicrobial peptides and for metal oxide nanoparticles with negative surface potential as a 
result of their strong interaction with P. aeruginosa and E. coli membranes, respectively5,42. Bleb morphology in 
E. coli has also been reported for the human antimicrobial peptide defensin 5, where the cause of bleb formation 
was localization of this peptide at the site of cell division and site poles indicating that the antibacterial activity 
is exerted in the cytoplasm43. Additionally, E. coli treated with the cationic antimicrobial peptide, gramicidin, 
illustrated a high degree of blister and dimple formation44. Filamentation, a continuous cell elongation which 
does not result in cell division, is often observed in bacteria as a result of various stress responses such as those to 
beta lactams and fluoroquinolones antibiotics45,46. Bacterial filamentation has been reported as a consequence of 
induction of SOS response mechanism which is responsible for regulation of DNA damage repair47,48. Elongated 
Figure 6. Scanning electron micrographs of E. coli ATCC 25922 untreated and exposed to Peptoid 1 (at 
concentrations corresponding to 1× and 4 × MIC for a period of 1 and 4 hours. Cultures in log phase at 
2–4 × 107 CFU/ml. (A) Untreated E. coli at 1 hour. (B) E. coli treated with 1x MIC (16 μ g/ml) at 1 hour. (C) E. 
coli treated with 4x MIC (64 μ g/ml) at 1 hour. (D) Untreated E. coli at 4 hours. (E) E. coli treated with 1 × MIC 
(16 μ g/ml) at 4 hours, and (F) E. coli treated with 4 × MIC (64 μ g/ml) at 4 hours.
www.nature.com/scientificreports/
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bacteria were observed among the affected bacterial population indicative of inhibition of bacterial cell division 
(Figs 6E and 7B). In addition, from the quantitative data, the majority of the E. coli with cell length of 3 μ m were 
those treated with 1 × MIC concentration of peptoid 2 (Fig. 8). Antimicrobial compounds that act via bacterio-
static mechanisms (e.g. inhibition of protein and RNA synthesis) have been shown not to induce filamentation 
or increase cell size49. Therefore the increase in cell size in bacteria treated with peptoids could be due to possible 
inhibition of DNA processes inside the cell. These results indicate that peptoids can destabilize the membrane 
of E. coli causing pronounced damage that does not always lead to complete lysis and cell death, but to cell 
elongation.
Changes in size and DNA content. We used flow cytometry to measure the changes in cell size and 
nucleic acid content reflected by increased light scatter and fluorescence, respectively. Exponentially growing cells 
were challenged with both peptoids and ciprofloxacin and stained with propidium iodide (PI) cell impermeant 
dye. PI stains nucleic acids in cells with damaged membranes. Untreated cells retain constant DNA per cell size 
(Fig. 9). Bacteria treated with ciprofloxacin appear significantly bigger with overall decrease of DNA per cell size. 
Certain quinolone antibiotics such as ciprofloxacin or norfloxacin interact with DNA gyrase and topoisomerase 
IV causing DNA replication fork arrest and induction of SOS response in E. coli. This leads to inhibition of cell 
division and filamentation50–52. Ciprofloxacin is also shown not to affect the membrane integrity of E. coli even 
at high concentrations46,53. The bactericidal effect of ciprofloxacin demonstrated in the killing kinetics experi-
ments is in agreement with the decrease of DNA per cell mass obtained from the flow cytometry measurements. 
This effect is thought to be related to the release of free DNA ends from DNA gyrase-ciprofloxacin complex that 
ultimately leads to chromosomal DNA fragmentation20,54. The fluorescence signal from PI binding to nucleic 
acids in the cells may therefore indicate a different pathway of membrane disturbance to be involved in making 
the bacteria permeable to the dye55. Investigation into the effect of the peptoids on the cell size and DNA content 
demonstrated that cell size increased considerably with an increase in concentration for both peptoids. The over-
all effect of the peptoids was a substantial decrease in DNA per cell mass, which was concentration dependent 
and it occurred at faster rate for peptoid 2 when compared to that of ciprofloxacin. A similar dose dependent 
interaction between peptoid and bacterial plasmid DNA was confirmed using a gel retardation assay (Fig. 2, see 
Supplementary Material). At 1 × MIC the inhibition pattern was somewhat less pronounced for the peptoids in 
regards to ciprofloxacin demonstrating a possible distinctive antibacterial effect.
Figure 7. Scanning electron micrographs of E. coli ATCC 25922 untreated and exposed to Peptoid 2. 
Cultures in log phase at 2–4 × 107 CFU/ml. (A) Untreated bacteria at 4 hours, (B) Bacteria treated with 4 × MIC 
at 4 hours.
Figure 8. Quantification of E. coli size distribution. Data from 1 hour incubation with and without 1× (16, 
32 μ g/ml) and 4 × MIC (64, 128 μ g/ml) concentrations of Peptoids 1 and 2, respectively.
www.nature.com/scientificreports/
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Conclusions
Many antimicrobial peptides have been referred to as “dirty drugs” due to their ability to act via multiple mecha-
nisms which involve membrane permeabilization and inhibition of intracellular processes36,56. While dissecting 
the mode of action of lysine and tryptophan rich peptoids that mimic the structure of antimicrobial peptides, 
we have demonstrated that the growth inhibition ability of peptoids that show different killing kinetics is most 
likely based on the different charge density distribution and overall hydrophobicities. We show that the killing 
mechanism for peptoid 1 is not fully attributed to its ability to cause leakage from the membranes as observed 
in the dye leakage assays. However, the killing mechanism is definitely supported by some degree of membrane 
damage exerted by this peptoid. Higher degree of bacterial lysis through membrane damage is observed for 
peptoid 2. The peptoids exhibited potent killing kinetics which are not explained solely by their membrane per-
meabilization ability, measured by calcein leakage from lipid vesicles mimicking bacterial membranes. However, 
the high degree of membrane disturbance measured by Live/Dead assay is not directly translated into a decrease 
of viable cells. The membrane disruptive ability is also supported by scanning electron micrographs of E. coli 
treated with both peptoids. Although the mechanism behind the observed increase in size is not clear, it can be 
reasonably assumed that besides the peptoids effect on the outer membrane they enter the cytoplasm and bind 
to internal targets thus inhibiting DNA, RNA or protein synthesis. Taken together we propose that these pep-
toids act via combined mechanism of action involving membrane disruption with probable intracellular targets. 
Further investigations are needed to support their effects via intracellular targets. The peptoids in this study have 
low toxicity, high stability and low cost of synthesis, properties which contribute to their high potential as new 
peptidomimetics with therapeutic applications.
Experimental Section
Materials and Bacterial strains. The strains used in the present study were from our laboratory strain 
collection. Escherichia coli (ATCC 25922) was obtained from the American Type Culture Collection (ATCC, 
Rockville, Md.). Other strains include Pseudomonas aeruginosa PAO1 H103 strain and Liverpool epidemic clin-
ical strain H1027, and Escherichia coli clinical isolate expressing extended spectrum β –lactamases (ESBL)57. All 
tested bacterial strains are categorized as biohazard level 2 pathogens.
Peptoid synthesis. Peptoids were synthesized using standard submonomer solid-phase synthesis, as 
described previously12.
In vitro susceptibility studies. Minimum inhibitory concentrations (MIC) for the peptoids have been 
measured as described previously12.
Killing kinetics. The kinetics of antimicrobial activity against E. coli (ATCC 25922) were assessed at a peptoid 
concentration corresponding to 1× , 2× and 4 × MIC. Briefly, an overnight culture of bacteria was diluted 1:50 
in fresh Mueller Hinton broth and regrown to an OD600 of 0.4 before diluting to a turbidity of 0.1. The bacterial 
suspension was added to a 96-well polystyrene flat bottomed plate containing the peptoid of interest in addition 
to known antibiotics. The plate was incubated without shaking at 37 °C for 180 minutes. Samples (100 μ l) were 
taken at time 20, 40, 80, 120 and 180 minutes and diluted in ice cold 0.9% NaCl from which 100 μ l was plated on 
LB agar plates. The plates were incubated for 18–24 hours at 30 °C and colony forming units (CFU) were counted. 
Sterility control was performed by plating 100 μ l of MH broth and 0.9% NaCl. Plates where no detectable bacterial 
growth was observed were left for additional 18 hrs incubation.
Live/Dead Staining. Overnight culture of E. coli ATCC 25922 was diluted 100-fold in fresh MH broth and 
allowed to grow until it reached OD600 of 0.1. Duplicate samples of 1 ml each were transferred to eppendorf tubes 
and pelleted at 10.000 g for 8 minutes. One sample was resuspended in 1 ml 0.9% NaCl and the other in 50 μ l 
0.9% NaCl followed by addition of 950 μ l 70% isopropyl alcohol to kill the bacterial. The tubes were left for 1 hour 
on ice with manual shaking every 15 minutes. The tube containing dead bacteria was pelleted at 12.000 rpm for 
8 min and resuspended with 1 ml 0.9% NaCl to remove the isopropyl alcohol. Five different ratios corresponding 
to 0, 10, 50, 90 and 100% of live bacteria were prepared to obtain the standard curve for the analysis of bacterial 
Figure 9. Flow cytometry data of exponentially growing E. coli exposed to Peptoids 1 and 2 and 
ciprofloxacin at concentrations corresponding to 1× and 4 × MIC. Fluorescence corresponds to cellular 
DNA content and lightscatter is equivalent to the bacterial cell size, thus fluorescence/lightscatter is a measure of 
the DNA content per cell mass. Results are from 3 independent experiments with SEM error bars.
www.nature.com/scientificreports/
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viability when challenged by antimicrobials (Fig. 1, see Supplementary Material). Briefly, 100 μ l of the staining 
solution (3 μ l of 3.34 mM SYTO 9 and 3 μ l of 20 mM propidium iodide in water) was added to 100 μ l of the dif-
ferent bacteria ratios containing wells and incubated in dark for 15 minutes before reading on multi-detection 
macroplate reader Synergy HT. The green fluorescence (SYTO 9) corresponds to the amount of live bacteria and 
was excited at 485 nm and the emission detected at 528 nm. The red fluorescence (propidium iodide) was excited 
at 530 nm and detected at 645 nm which correspond to the amount of dead bacteria in the sample. Bacteria sus-
pension challenged with antimicrobial for viability analysis were prepared by incubating 90 μ l of bacteria (OD600 
of 0.1) and 10 μ l antimicrobials for 5 hours during which period samples were extracted in PCR tubes at 0, 10, 20, 
40, 80 and 120 minutes and immediately put on ice. All PCR tubes were pelleted at 10.000 g for 8 minutes before 
being resuspended in cold 0.9% NaCl and placed on ice again. The content of each PCR tube was then added to 
individual wells of flat bottomed polystyrene 96 microtitter plate and mixed with 100 μ l staining solution. After 
15 minutes incubation in dark the fluorescence was measured using multi-detection microplate reader Synegry 
HT. The percentage of living cells was calculated using Equation 1 below.
.
= ×live cells Green fluorescence
Red fluorescence
1
0 108
% (1)
Liposome preparation. Two different compositions of large unilamellar vesicles (LUVs) were made. To 
mimic the composition of bacterial membranes 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphoglycerol (POPG) 
and 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (POPC) in a molar ratio of 7:3 was prepared. The second 
composition, a simple mimic of mammalian membranes, was made from POPC:POPG:Cholesterol in a molar 
ratio of 5:2:3. The indicated lipids were purchased from Avanti Lipids (Alabaster, Alabama). The lipid mixtures 
were initially mixed in chloroform, after which the solvent was removed under low pressure at 40 °C in a rotary 
evaporator over 2 hours. Ethanol (99.9%) was frequently added to remove residual organic solvent. The lipid mix-
ture was then dissolved in 4 ml HEPES buffer (10 mM HEPES, 150 mM KCl, 0.03 mM CaCl2, 0.01 mM EDTA. pH 
7.4) with 20 mM calcein (C0875, Sigma), for calcein containing liposomes. Multiple mixing and sonication steps 
for 5 minutes were performed to avoid aggregation. Subsequently, the lipid mixture was vigorously whirl-mixed 
every 10 minutes over a course of 1 hour and finally left at room temperature for an additional hour to allow the 
lipids to anneal. LUVs were prepared by extruding the lipid mixtures through double stacked 100 nm filters, 
a total of 10 times using Nitrogen powered extruder and 30 bars pressure. Calcein containing liposomes were 
loaded on Sephadex G-50 columns to separate encapsulated from free calcein and the elution was done using 
calcein free HEPES buffer. For verification of the size of the liposomes, dynamic light scattering (DLS) measure-
ments were obtained on a Zetasizer Nano ZS (Malvern, Worcestershire, UK). Monodisperse liposomes of a size 
of 110 nm was measured by Malvern DTS v. 5.10 software.
Liposome quantification. Quantification of lipid content was performed using standard protocols 
described previously58. Initially, standard curve was obtained using 0, 20, 40, 60, 80, and 100 nmols of standard 
potassium phosphate solution (1 mM). Briefly, the tubes containing 0, 20, 40, 60, 80 and 100 μ l of potassium 
phosphate buffer were dried in a heating block at 120 °C and 400 μ l of perchloric acid (HClO4) was added. For 
determination of the lipid content of the prepared liposomes, 50 nmols were dried and 400 μ l of perchloric acid 
was added. Digestion of the lipids was achieved by heating the suspension at 180 °C for up to 2 hours. After all 
samples have been cooled to room temperature, 1 ml of MilliQ water is added, followed by addition of 400 μ l of 
ammonium molybdate (1.252 g/100 ml). All the tubes are vortexed and 400 μ l of freshly prepared ascorbic acid 
(3% w/v) is added. The tubes are put to boiling water for 10 minutes and after they cool down, 1 ml is transferred 
to a 1 cm cuvettes and absorption is read using standard spectrophotometer at 797 nm. Using the standard curve 
equation, the concentration of liposome suspension was calculated before use.
Calcein release assay. Calcein release was done in a 96-well plate with shielded wells (MicroWell 96 optical 
bottom plate, NUNC, Roskilde, DK) as previously described16. Briefly, peptoids were diluted in 10 mM HEPES 
buffer and 100 μ l were added to wells followed by addition of 80 μ l of 45 μ M liposomes suspension for a final 
liposome concentration of 20 μ M. Immediately after addition the fluorescence was read using multi-detection 
microplate reader Synergy HT at an excitation wavelength of 485 nm and an emission wavelength of 520 nm 
over a course of 1 hour at 37 °C. Maximum calcein release was acquired using 10% Triton X-100 and release fol-
lowing peptoid exposure was calculated using equation 2, where F and Fo represent the initial and the final levels 
of fluorescence before and after peptoid addition, respectively, and Fmax is the fluorescence level after complete 
disruption of liposome by addition of detergent, 10% Triton X-100.
= ×
−
−
calcein release 100 F Fo
Fmax Fo
% (2)
Carboxyfluorescein leakage assay. The permeabilizing activity studies of the peptides upon model mem-
branes were performed as previously described59. This test is based on the property of self-quenching of carbox-
yfluorescein when in high concentrations, and high quantum yield when diluted. Stock solutions of the lipids 
were prepared in chloroform:ethanol mixture. Lipid films were obtained by evaporating the solvent from pre 
aliquoted mixtures of the stock solutions under a stream of N2 and submitted to vacuum for 2 hours. The lipid 
film is then resuspended in a 50 mM solution of carboxyfluorescein with Tris-HCl 20 mM and NaCl 300 mM 
and pH 7.4. The lipid suspension is extruded through two stacked polycarbonate filters with 100 nm pore size 
(Nuclepore, Maidstone, UK) to obtain the large unilamellar vesicles (LUV). At this stage, the suspension has 
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50 mM of carboxyfluorescein in the internal compartment of the LUV at the external environment. The LUV 
are separated from non-encapsulated carboxyfluorescein by a process of gel-filtration chromatography on a 
pre-packed Sephadex G-25 mini-column (GE Healthcare, Buckinghamshire, UK) equilibrated with the buffer. 
Lipids were further quantified by the Rouser method58. The total lipid concentration in the samples was 20 μ M. 
The carboxyfluorescein release was determined same as calcein release, described earlier (Eq. 2).
Scanning electron Microscopy (SEM). Overnight culture (approx. 18 h at 37 °C) of E. coli ATCC 25922 
was diluted 1:50 in fresh MH broth and regrown to an OD600 of 0.4 before diluting it to a turbidity of 0.1. Bacteria 
were treated with 1× and 4 × MIC concentrations of peptoids GN-2 Npm9 and GN-2 Nlys1–4 Ntrp5–8 prepared 
in MH Broth for 4 h at 37 °C in a microtitter plate. Samples were taken at two time points, one at 1 h and the sec-
ond at 4 h incubation. To ensure enough cells for analysis a volume of 600 μ l (3 × 200 μ l) was polled into 1.5 ml 
Eppendorf tubes. The sample was then chemically fixed in 3% glutaraldehyde in MHB, pH adjusted to 7.3 at 4 °C 
for 16 hrs. After washing 3 times in distilled water, for 10 min each time, the sample was stained with 1% OsO4 
at 4 °C for 16 hrs. Next, the sample was washed again, 3 times, and dried in ethanol series at 25 °C for 10 minutes 
for each ethanol step (30, 50, 70, 80, 90 and 100% ethanol). The 100% ethanol was replaced with acetone in three 
10 minute steps: 30, 50 acetone and 100% acetone. After the acetone step, the sample was further dried in a Leica 
EM CPD300 onto a square piece of silicon wafer. The silicon substrate with the dried sample was attached onto 
an aluminium stub with a double sided C tape, and the sample was coated with 2 nm Pt in a Cressington 208HR 
High Resolution Sputter Coater. The sample was then imaged in an FEI Helios dual beam scanning electron 
microscope by monitoring the secondary electron signal at 2 keV and 43 pA with the through the lens detector. 
The size analysis was performed using the NIH public domain Image J.
Flow cytometry. Overnight culture of Escherichia coli ATCC 2592 was diluted 1:50 in fresh MH broth and 
allowed to grow until an OD600 of 0.1. This suspension is further 10-fold diluted and regrown till OD600 of 0.1 to 
ensure a uniform bacterial population. A volume of 90 μ l of bacterial suspension was loaded to a flat bottomed 
96-well Greiner plate. After extraction at zero minutes, 10 μ l of the peptoid and antibiotics corresponding to 1× 
and 4 × MIC concentrations was loaded to the bacteria containing wells for a total volume of 100 μ l. Samples were 
collected at 20, 40, 80,120 and 180 minutes and put on ice. The plate was sealed and incubated at 37 °C between 
sample extractions. Samples from wells containing bacteria without peptoids or antibiotics were taken at each 
time point. The samples were, whenever appropriate, centrifuged at 10.000 × g for 5 min at 4 °C. The supernatant 
was carefully removed and the bacteria were resuspended in 100 μ l 10 mM Tris HCl pH 7.4. 1000 μ l of ice cold 
77% Ethanol was added before storing the samples at 4 °C until analysis. Rifampicin/Cephalexin samples were 
prepared by collecting 200 μ l from the wells containing bacteria and the appropriate antimicrobial in an E-tube 
containing 45 μ l of a mixture of Rifampicin (300 μ g/ml) and Cephalexin (36 μ g/ml). The tube was placed in a 37 °C 
shaking water bath for 2½ hours after which the samples were treated in the same way as the other samples before 
storing them at 4 °C. To monitor the bacterial growth the plate was read before each sample was extracted in a 
multi-detection plate reader Synergy HT. The following day, the samples were centrifuged at 10.000 × g for 5 min 
and the supernatant was carefully removed. The samples were stained for flow cytometry analysis with 140 μ l of 
staining solution (90 μ g/ml Mitramycin and 20 μ g/ml Ethidium Bromide in 10 mM Tris pH 7.4, 10 mM MgCl2). 
For flow cytometry analysis A10 Bryte Flow Cytometer was used and around 20.000 events were included.
DNA binding assay. el retardation experiments were performed by mixing 100 ng of bacterial plasmid DNA 
(pBluescriptII SK+ , # 212205 Stratagene) with different concentrations of both Peptoids 1 and 2 in 20 μ l binding 
buffer (5% glycerol, 10 mM Tris-HCl (pH 8.0), 1 mM EDTA, 1 mM dithiothreitol, 20 mM KCl, and 50 μ g/mL 
bovine serum albumin). The reaction mixtures were incubated for 1 h at room temperature before running 20 μ l 
aliquot on a 1% agarose TAE (Tris-acetate-EDTA) gel using 1× TAE buffer in the electrophoresis chamber at 
125 V.
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